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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.031Vascular endothelial growth factor (VEGF) A is generated as two isoform families by alternative RNA
splicing, represented by VEGF-A165a and VEGF-A165b. These isoforms have opposing actions on vascular
permeability, angiogenesis, and vasodilatation. The proangiogenic VEGF-A165a isoform is neuro-
protective in hippocampal, dorsal root ganglia, and retinal neurons, but its propermeability, vaso-
dilatatory, and angiogenic properties limit its therapeutic usefulness. In contrast, a neuroprotective
effect of endogenous VEGF-A165b on neurons would be advantageous for neurodegenerative patholo-
gies. Endogenous expression of human and rat VEGF-A165b was detected in hippocampal and cortical
neurons. VEGF-A165b formed a signiﬁcant proportion of total VEGF-A in rat brain. Recombinant human
VEGF-A165b exerted neuroprotective effects in response to multiple insults, including glutamatergic
excitotoxicity in hippocampal neurons, chemotherapy-induced cytotoxicity of dorsal root ganglion
neurons, and retinal ganglion cells (RGCs) in rat retinal ischemia-reperfusion injury in vivo. Neuro-
protection was dependent on VEGFR2 and MEK1/2 activation but not on p38 or phosphatidylinositol
3ekinase activation. Recombinant human VEGF-A165b is a neuroprotective agent that effectively
protects both peripheral and central neurons in vivo and in vitro through VEGFR2, MEK1/2, and inhi-
bition of caspase-3 induction. VEGF-A165b may be therapeutically useful for pathologies that involve
neuronal damage, including hippocampal neurodegeneration, glaucoma diabetic retinopathy, and
peripheral neuropathy. The endogenous nature of VEGF-A165b expression suggests that noneisoform-
speciﬁc inhibition of VEGF-A (for antiangiogenic reasons) may be damaging to retinal and sensory
neurons. (Am J Pathol 2013, 183: 918e929; http://dx.doi.org/10.1016/j.ajpath.2013.05.031)Supported by Wellcome Trust grants 079736 and 058083 and the
Richard Bright VEGF-A Research Trust.
N.B.-L. and J.H. contributed equally to this work.
D.O.B. and L.F.D. contributed equally to this work as senior authors.
Current address of J.H., Department of Ophthalmology, Schepens Eye
Research Institute, Boston, MA; of D.O.B., Division of Preclinical Oncology,
University of Nottingham Queen’s Medical Centre, Nottingham, UK.Vascular endothelial growth factor (VEGF) A, originally
described as a potent vascular permeability and growth factor
for endothelial cells, is up-regulated in the brain during stroke
and ischemic episodes1 and has been linked with many
neuronal diseases. The most widely studied isoform of
VEGF-A, VEGF-A165a, is up-regulated in hypoxia, induces
increased vascular permeability in neuronal vasculature, and
can stimulate angiogenesis after ischemic episodes. The
resulting edema and hyperemia can be damaging, but VEGF-
A165a has also been found to have direct anticytotoxic effects
on neurons, raising the possibility that it may act as anstigative Pathology.
.endogenous neuroprotective agent in neurodegenerative
pathologies. VEGF-A exerts neurotrophic (survival) and
neurotropic (neurogenesis and axon outgrowth) actions,
which, although initially thought to be a function of increased
Neuroprotective VEGF165bangiogenesis and perfusion after neuronal injury,2 are now
appreciated as direct effects of VEGF-A on neurons.
The vegfa gene encodes numerous products by differen-
tial splicing, but not all isoforms exert the same effects.3
Alternative splicing of exon 8 leads to two functionally
distinct families: the proangiogenic VEGF-Axxxa family and
the counteracting VEGF-Axxxb family.
4,5 VEGF-A165b
prevents the VEGF-A165a effects on increased vascular
permeability, blood vessel growth, and vasodilatation.4e7
The therapeutic potential of VEGF-A and antieVEGF-A
treatments are now widely recognized, and effective antie
VEGF-A treatments are available in ophthalmology8 and
oncology.9 The ﬁnding that VEGF-A is implicated in neuronal
disorders (eg, Alzheimer disease, Parkinson disease, Hunting-
ton disease, diabetic neuropathy, and amyotrophic lateral scle-
rosis10) provides a rationale for the use of VEGF-A as
a therapeutic agent in neurodegenerative conditions. Although
this rationale is supported by preclinical evidence,11 the iden-
tiﬁcation of the VEGF-Axxxb family requires reexamination of
VEGF-A isoforms in these contexts to allow for the clear
evidence that VEGF-A splicing variants are not functionally
equivalent3 and to determine whether augmentation of the
proangiogenic isoform family (VEGF-Axxxa) alone may have
deleterious effects (eg, in occult malignancy and carcinoma
in situ).
The neuroprotective proﬁle of the exon 8 alternatively
spliced isoforms VEGF-Axxxb remains unexplored. Inter-
estingly, VEGF-Axxxb isoforms do not exhibit the vascular
effects seen with VEGF-Axxxa isoforms, such as a sustained
increase in capillary permeability or hypotension.5,12 The
lack of these potential adverse effects may make VEGF-
Axxxb isoforms more amenable as therapeutic agents in
neurodegenerative diseases.
We therefore tested the hypothesis that VEGF-A165b is
neuroprotective for central and peripheral neurons. We
found that VEGF-A165b is expressed in central neurons and
is neuroprotective in vitro and in vivo. This ﬁnding indicates
that VEGF-A165b may prove to be a suitable therapeutic
agent in neurodegenerative disorders, exhibiting fewer
adverse effects than VEGF-A165a.
Materials and Methods
All reagents were sourced from Sigma-Aldrich (Dorset, UK)
unless otherwise stated. Antibodies were sourced from R&D
Systems (Carlsbad, CA) [aVEGF-A165b (monoclonal anti-
body [mAb] 3045), a-caspase-3, aTrkA, and aNF-200] or
Cell Signaling Technology (Danver, MA) [phospho-p44/42
mitogen-activated protein kinase (MAPK) (9106) and p44/
42 MAPK (9102)]. Recombinant human (rh) VEGF-A165b
was provided by Philogene (New York, NY) or from R&D
Systems. Computer-aided analysis of immunohistochemistry
(IHC), retinal Fluorogold staining, and cytotoxicity was per-
formed using Macintosh computers running public domain
ImageJ version 1.46 plus Cell Counter Plugin (NIH, Bethesda,
MD; available at http://rsb.info.nih.gov/nih-image).The American Journal of Pathology - ajp.amjpathol.orgProtein Assessment by IHC and ELISA
VEGF-A protein was localized in ﬁxed or frozen tissue
sections using standard immunohistochemical/immunoﬂu-
orescent techniques13 or was measured in tissue extracts by
commercially available ELISA using a VEGFxxxb-speciﬁc
capture antibody and a pan-VEGF detection antibody for
VEGFxxxb isoforms or two pan-VEGF antibodies for total
VEGF, as previously described.5 Total VEGF-A and
VEGF-A165b were detected using validated, commercially
available antibodies. The VEGF-A165b antibody detects the
unique C-terminal of the alternatively spliced VEGF-Axxxb
family.5,14 Difﬁculties in the accurate detection of endoge-
nous VEGF isoforms in rodents have been highlighted
recently15 in that the use of mouse antibodies to mouse
tissues can detect proteins of similar size to the VEGF165b
homodimer and heterodimer. These bands are also found if
the primary antibody is omitted, indicating that anti-mouse
secondary antibodies detect mouse IgG. The use of human
and rat tissue sidesteps this issue because the anti-mouse
IgG does not detect human or rat IgG. To conﬁrm speci-
ﬁcity of staining a nonspeciﬁc mouse IgG control was used
at the same concentration and under the same conditions,
a second negative control where the primary antibody was
incubated for 6 hours at 4C in eight times the concentration
of rhVEGF165b as a peptide block before continuing the
IHC under the same conditions, and a positive control where
the primary antibody was incubated for 6 hours at 4C in
eight times the concentration of rhVEGF165a before
continuing the IHC under the same conditions. Human
embryonic and adult tissues were obtained under ethical
approval by the North Bristol National Health Service Trust
or the University of Leiden. All procedures using animals
were performed in accordance with the United Kingdom
Animals (Scientiﬁc Procedures) Act 1986 and with
University of Bristol Ethical Review Panel approval.
Excitotoxicity
Glutamate-induced hippocampal neuronal excitotoxicity
was assessed in cultures of neonatal hippocampal neurons
from twelve 2-day-old CD1 mouse pups as previously
described.16 Neurons were cultured on polylysine-coated
glass coverslips in 6 well plates (37C, ambient oxygen,
and 5% CO2, 400,000 cells per plate) in neuronal growth
media plus B-27 supplement (GIBCO-Invitrogen, Paisley,
UK) with penicillin and streptomycin and 1% bovine serum
albumin. After 24 hours, cultures were supplemented with
10 mg/mL of 5-ﬂuoro-20-deoxyuridine to inhibit growth of
nonpostmitotic satellite cells. Excitotoxicity assays were
started on day 10 of culture. Cultures were exposed to 3
mmol/L L-glutamic acid for 24 hours in the presence of
VEGF-A165b (0.01, 0.1, 1, and 10 nmol/L) or 50 nmol/L
galanin (Bachem). To determine the mechanism of VEGF-
A165bemediated effects, additional cultures were incubated
with VEGF-A165b in the presence of VEGF-A receptor and919
Beazley-Long et aldownstream signaling molecule inhibitors PTK787
(Novartis, New York, NY), SU5416 (Sugen, New York,
NY), ZM323881 (AstraZeneca, Wilmington, DE), and
PD98059 (Calbiochem, Billerica, MA). Cytotoxicity was
assessed by a trained observer masked to treatment using
a Live/Dead Viability/Cytotoxicity Kit (Molecular Probes-
Invitrogen, Paisley, UK). The cells were ﬁxed and nuclei
stained (Hoechst 33258; 1:2300) and mounted to a glass
slide. For quantitation purposes, only cells with positive
nuclear staining with Hoechst 33258 were counted. Ten
random images of each coverslip were taken.
Chemotherapy-Induced Cytotoxicity
Oxaliplatin-induced dorsal root ganglion (DRG) neuronal death
was assessed in primary cultures of adult rat DRG neurons.
DRG was dissected and enzymatically and mechanically
dissociated, and the cells were plated onto poly-L-lysine- and
laminin-coated coverslips at approximately 2850 cells/cm2 in
Ham’s F12 with N2 supplement (Gibco 17502)þ0.3% bovine
serum albumin. A total of 30 mg/mL of 5-ﬂuoro-20-deoxyur-
idine was added to prevent nonpostmitotic cells from prolifer-
ating. DRG neurons were cultured for 2 days before overnight
pretreatment with test compounds (2.5 nmol/L rhVEGF-A165b,
10 nmol/L rhPlGF, 0 to 100 mg/mL of anti-VEGF165b, 0 to 100
mg/mL of mouse IgG, 10 nmol/L ZM323881, or vehicle).
Neurons were then treated with oxaliplatin for 24 hours with
test agent or vehicle. Neurons were treated with PrestoBlue Cell
Viability Reagent (Molecular Probes; A-13261) for detection of
cell viability and absorbance read on a ﬂuorescence plate-reader
(PerkinElmer, Waltham, MA), treated with trypan blue for
detection of viable cells and trypan blueepositive percentage
determined by manual counting, or ﬁxed in 4% para-
formaldehyde and subjected to immunoﬂuorescence for the
detection of activated caspase-3 (200 ng/mL of Rab mAb
overnight; Cell Signaling). Neurons were identiﬁed by co-
staining with markers NeuN (MAB377; Millipore, Billerica,
MA), bIII-tubulin (TU20; Abcam, Cambridge, UK), or neuron-
speciﬁc enolase 1. The percentage of caspase-3epositive
neurons were analyzed by a trained observer masked to treat-
ment. In separate experiments, VEGFR2 expression was
detected using a rabbit VEGFR2 mAb (1:500, overnight,
50b11; Cell Signaling). The primary antibody was replaced by
concentration- and species-matched IgG to control for each
immunoﬂuorescence experiment.
Western Immunoblotting
Rat immortalized sensory neuronal cells (50B1117) were
used for protein analysis after VEGF-A165b treatment
because of the larger protein content available from these
cells compared with that from primary cultures. They were
grown to approximately 80% conﬂuence, differentiated with
75 mmol/L forskolin (catalog no. F6886) for 24 hours, and
treated with  .1 nmol/L rhVEGF-A165b, directly to the
media for 10 minutes. Protein was extracted in920radioimmunoprecipitation assay buffer with protease inhib-
itor cocktail plus 2 mmol/L NaVO4, separated by SDS-
PAGE (12%), and blotted onto polyvinylidene diﬂuoride
membrane. This was blocked in 2% bovine serum albumin
Tris-buffered salineeTween (0.05%) for 1 hour, and anti-
p44/42 MAPK (Rab polyclonal antibody, no. 9102, 1 in
500; Cell Signaling) and antiephospho-p44/42 (mouse mAb,
no. 9106, 1 in 250; Cell Signaling) were added in blocking
solution and incubated overnight at 4C. Fluorescent
secondary antibodies (LI-COR, Lincoln, NE) were added 1 in
10,000 in blocking solution for 1 hour at room temperature
and ﬂuorescence visualized on a LI-COR Odyssey.
Neurite Outgrowth
The effect of VEGF-A165b on neurite outgrowth in cultured
rat primary DRG neurons was assessed as previously
described.18 Adult DRG neurons were cultured with or
without 1 nmol/L VEGF-A165b for 24 hours and the length
of neurite outgrowth assessed.
RGC Death in Vivo
A total of 27 male Wister rats (250 to 350 g; Charles River,
Wilmington, MA) were used to assess the effect of VEGF-
A165b on RGC death after ischemia. One week before
ischemia/reperfusion injury, RGCs were retrogradely labeled
with Fluorogold using a previously described method.19,20
Brieﬂy, Fluorogold (4% in PBS; Fluorochrome Inc, Den-
ver, CO) was injected into bilateral superior colliculi (0.6 mL
at 4.2-mm depth and 0.7 mL at 4.7-mm depth) under iso-
ﬂurane inhalation anesthesia (1-minute induction at 5% in
oxygen, reduced to 3% for maintenance) and sterotaxic
guidance. Fluorogold is retrogradely transported in RGCs,
and somatic labeling is maintained for at least 3 weeks.21
Animals were randomly assigned to 1 of 3 groups: 12
animals received an intravitreal injection of 10 ng of VEGF-
A165b in 5 mL of HBSS in one eye, seven received the same
volume of HBSS, and eight were untreated. Twenty-four
hours after intraocular injection, animals were subject to
retinal ischemia as previously described.19,20 Under iso-
ﬂurane anesthesia and stereotaxic guidance, the pupil was
dilated (1% tropicamide and 2.5% phenylepherine eye
drops), and anterior chamber pressure was maintained for 60
minutes with 0.9% NaCl infusion that elevated the intraocular
pressure to 120 mm Hg. The cessation of the retinal blood
ﬂow was observed using direct funduscopy during the
procedure. Reperfusion of retinal vessels was observed as
intraocular pressure reduced after cessation of perfusion.
Twenty-four hours after ischemia, retinas from three animals
from each group were stained for activated caspase-3
immunoﬂuorescence to assess the extent of ischemic
damage.22 Caspase-3epositive cells were counted indepen-
dently in the retinal ganglion and inner nuclear layers. The
remaining animals were euthanized with isoﬂurane overdose
10 days after ischemia and the numbers of survivingajp.amjpathol.org - The American Journal of Pathology
Neuroprotective VEGF165bFluorogold-labeled neurons counted. Cell counts were per-
formed by an operator masked to treatment.
Partial Saphenous Nerve InjuryeInduced Cell Death
Partial saphenous nerve injury (PSNI) on C57/Bl6 mice was
performed as previously described23 with the mice underFigure 1 VEGF-A165b is expressed in human and rat hippocampus.
Human cortical sections from the Human Tissue Authorityelicensed South
West Dementia Brain Bank were stained with an antieVEGF-A165b antibody.
Hippocampal staining in CA1 (A), CA2 (B), CA3, and dentate gyrus (DG; C).
D: Negative control mouse IgG staining of the hippocampus. High-power
view of DG stained with mouse IgG (right panel). E: Anti-VEGF165b anti-
body preincubated with rhVEGF165b reveals no staining of the hippocampus.
High-power view (right panel). F: Anti-VEGF165b antibody preincubated
with rhVEGF165a reveals similar staining of the hippocampus. G: Protein was
extracted from cortex and hippocampus dissected from rat brains (n Z 3)
and subjected to ELISA for VEGF-A and VEGF-Axxxb. VEGF-Axxxa levels were
estimated from the difference between total VEGF-A and VEGF-Axxxb. H:
Percentage of total VEGF-A that is VEGF-Axxxb.
The American Journal of Pathology - ajp.amjpathol.orgisoﬂuorane anesthesia (2% to 3% in oxygen). An incision
(approximately 5 mm) was made in the inguinal fossa region
of the right hind leg. Fifty percent of the saphenous nerve was
tightly ligated using a size 6.0 sterile silk suture, and the
wound was closed with size 4.0 sterile silk suture. Animals in
the sham surgery group (n Z 5) underwent anesthesia and
surgery that involved solely an incision in the inguinal fossa
region of the right hind limb. Each PSNI experimental group
received biweekly VEGF-A165b (n Z 6, 20 ng/g) or PBS
vehicle (nZ 16, 200 mL). Sham surgery involved the exact
same procedure, except without the tight ligation of the
saphenous nerve. Controls in the sham surgery group (nZ 5)
received i.p. PBS at the same times. Injections were given
immediately after surgery, and animals were sacriﬁced after
10 days by overdose of anesthetic and perfuse ﬁxation with
4% paraformaldehyde. DRG sections (10 mm thick) were
dissected out, frozen, and stained for activating transcription
factor 3 (ATF3, cat no sc188; Santa Cruz, Santa Cruz, CA).
Statistical Analysis
Numbers of repetitions and animals are given in the text
and/or ﬁgures. All data were analyzed using t-tests (two
groups) or one-way analysis of variance and either Student’s
Newman Keuls post hoc test (when all columns are
compared with each other) or Bonferroni post hoc tests
when a priori speciﬁc tests were used, unless data were
ordinal or obviously nongaussian, in which case nonpara-
metric equivalents were used.
Results
IHC of human brain samples demonstrated that VEGF-A165b
was strongly expressed in the human hippocampal region
(Figure 1A), throughout all three pyramidal regions (CA1,CA2,
and CA3) (Figure 1B), and the dentate gyrus (Figure 1C), with
neurons also being expressed in occasional neurons scattered
through the cortex. The use of a mouse IgG at the same
concentration or preincubation of the primary antibody with
recombinant VEGF165b demonstrated no signiﬁcant staining
(Figure 1, D and E). Preincubation with recombinant
VEGF165a, however, did not block the staining (Figure 1F). To
quantify expression, protein was extracted from rat brains and
VEGF-Axxxb and total VEGF-A levels measured by ELISA.
VEGF-Axxxb levels averaged 45%and41%of totalVEGF-A in
the cortex and hippocampus, respectively (Figure 1, G and H).
Because VEGF-Axxxa splice variants are known to be
neuroprotective, we assessed the effectiveness of VEGF-
Axxxb splice variants as neuroprotective agents in hippo-
campal neurons, central nervous system neurons that are
particularly vulnerable to damage.
RhVEGF-A165b reversed glutamate-induced hippocampal
neuronal death in a concentration-dependent manner
(Figure 2, A and B) and was no less potent than galanin, which
has previously been described as a potent hippocampal neu-
roprotective agent16 (Figure 2B). At 10 nmol/L, the maximum921
Beazley-Long et alVEGF-A165b concentration used, cell death was the same as
untreated cells, revealing complete inhibition of excitotoxicity.
VEGF-A165b is a weak partial agonist at VEGF-A receptor 2
(VEGFR2, also known as Flk1) in vitro.24 In hippocampal
neurons, the neuroprotective action of VEGF-A165b was
dependent on VEGFR2 activation (Figure 2C), as has been
described for VEGF-A165a.
25 The partial reversal of excito-
toxic cell death seen in the presence of VEGF-A165b was
blocked by the 100 nmol/L VEGFR blockers PTK787 (PTK,
blocks both VEGFR1 and VEGFR226) and 10 nmol/L
ZM323881 (ZM, blocks VEGFR227) but was unaffected by
SU5146 (SU, at 100 nmol/L has speciﬁcity for VEGFR112).
Hippocampal neurons in culture expressed VEGFR2
(Figure 2D). Hippocampal neuroprotection elicited by VEGF-
A165b was dependent on downstream signaling of the
VEGFR2 through the p44/42 MAPK pathway (Figure 3A), as
it was also blocked by the MEK2 inhibitor, 10 mmol/L
PD98059, as is also the case for VEGF-A165a.
28 Neuro-
protection was not affected by blockade of either p38 MAPK
by SB203580 or phosphatidylinositol 3ekinase (PI3K) with
LY294002 (Figure 3, A and B). Treatment of 50B11 neurons
with VEGF-A165b signiﬁcantly increased p44/42 MAPK
phosphorylation (Figure 3C), which was blocked by the
inhibitor PD98059 (Figure 3D).
VEGF-A165b also exerted a neuroprotective action on
retinal neurons in vivo (Figure 4). In retinal ischemia
a reduction in retrograde transport of ﬂuorescent tracer was
seen (Figure 4A). This ischemic neuronal loss was reversedFigure 2 VEGF-A165b is protective against glutamate-induced hippocampal
neurons exposed to glutamic acid, with and without VEGF-A165b or galanin. Cells c
purple and represent approximately 75% of glutamic acidetreated neurons under c
on excitotoxicity in neurons co-incubated with 3 mmol/L glutamate. B: VEGF-
excitotoxicity in hippocampal neurons (P < 0.0001, n Z 4, analysis of variance
VEGF-A receptor inhibitors on the hippocampal neuroprotective effect of VEGF
ZM323881 (VEGFR2-speciﬁc antagonist), and 100 nmol/L SU5416 (VEGFR1-speciﬁ
group]. D: VEGFR2 (red) expression in b3-tubulinepositive (green) neurons. Nuclei
membrane staining of the VEGFR2 outside tubulin.
922by prior intraocular VEGF-A165b treatment (Figure 4A). To
determine whether this was due to apoptosis, retinae were
stained for active caspase-3 (Figure 4B). Uninjected and
HBSS-injected ischemic eyes revealed signiﬁcant retinal
neuronal loss through apoptosis, as assessed by Fluorogold
labeling of live neurons (Figure 4, C and D) and caspase-3
staining respectively (Figure 4E). The reduction in neuronal
retrograde transport was signiﬁcantly reversed by VEGF-
A165b (Figure 4, A, C, and D), when compared with the
uninjected contralateral eye and reduced apoptosis in both
RGCs and inner nuclear layer cells (Figure 4, B and D).
VEGF-A165a has been found to be cytoprotective against
injury induced by a variety of cellular insults to neurons.29
To determine whether neuroprotection was conﬁned to
central neurons or also affected peripheral neurons, cultured
primary DRG neurons were investigated. The addition of 1
nmol/L VEGF-A165b signiﬁcantly increased the length of
neurite outgrowth during 24 hours from 41.7  2.2 mm to
73.8  20 mm (P < 0.05, U-test) but did not affect the
number of DRG neurons in treated and control cultures,
indicating a neurotrophic action. A total of 2.5 nmol/L
VEGF-A165b signiﬁcantly prevented an increase in acti-
vated caspase-3 in primary DRG neurons induced by 24
hours of treatment with the chemotherapeutic oxaliplatin.
Treatment with oxaliplatin alone (5, 10, or 20 mg/mL)
signiﬁcantly increased the percentage of caspase-3epositive
DRG neurons compared with untreated neurons, and
VEGF-A165b prevented this (Figure 5, A and B).neuronal excitotoxicity. A: Pseudocolored image of cultured hippocampal
o-stained with Hoechst 33258 nuclear stain (blue) and Dead stain (red) are
ontrol conditions. Also note effect of treatment with 10 nmol/L VEGF-A165b
A165b has a concentration-dependent inhibitory effect on glutamatergic
plus Newman-Keuls post hoc test, *P < 0.01, **P < 0.001). C: Effect of
-A165b [100 nmol/L PTK787 (nonspeciﬁc VEGFR2 antagonist), 10 nmol/L
c antagonist); *P < 0.05 compared with control, **P < 0.01, n Z 4 per
are stained blue. Higher-power individual color images (right panel) reveal
ajp.amjpathol.org - The American Journal of Pathology
Figure 3 The effect of intracellular kinasee
pharmacological inhibition on VEGF-A165b neuro-
protection.A: Representative images of hippocampal
neurons subjected to the live/dead cell viability
stain after 24-hour treatment with 3 mmol/L L-glu-
tamic acid in the presence of test compounds or
respective vehicles. Neurons treated in culturemedia
alone (neurobasal media) or L-glutamic acid plus
2.5 nmol/L VEGF-A165b with or without 10 mmol/L
SB203580 (p38 MAPK inhibitor) or 15 mmol/L
LY294002 (PI3K inhibitor) maintained neurite
projections (arrows). In the presence of L-glutamic
acid plus VEGF-A165b plus 10 mmol/L PD098059
(MEK1/2 inhibitor) neurons retracted neurites
(arrowheads). Scale barZ 25 mm. B: The percentage
of red-stained (dead) nuclei per total nuclei stained
was calculated. More neurons died when treated with
the MEK1/2 inhibitor plus VEGF-A165b (PD) than when
treated with VEGF-A165b and vehicle (control).
Neither p38 MAPK (SB) nor PI3K (LY) inhibition had
any effect on the neuroprotection exerted by VEGF-
A165b. Data are means  SEM, nZ 3 of 4 one-way
analysis of variance plus Bonferroni post hoc
comparison; increase of cell death in glutamic acid
plus inhibitor/vehicle over media plus inhibitor/
vehicle (white bars) compared with increase of cell
death in glutamic acid plus VEGF-A165b and inhibitor/
vehicle (black bars), *P < 0.05, **P < 0.01. C: The
level of phosphorylated p44/42 MAPK detected by
immunoblotting was increased in cultured 50B11
neurons treated with 0.1 nmol/L rhVEGF165b
compared with control (nZ 3). D: PD98059 blocked
phosphorylation of p42/p44 MAPK induced by
VEGF165b in 50B11 neurons (*P < 0.05, **P < 0.01
compared with untreated).
Neuroprotective VEGF165bTo determine whether VEGF165b was acting as an
endogenous neuroprotective factor for DRG, we treated
cultured primary rat DRG cells with an antibody to
VEGF165b with or without the toxic chemotherapeutic oxa-
liplatin. In the absence of oxaliplatin, neither anti-VEGF165b
antibody (means  SEM, 98%  14%, 103%  12%, and
95%  6.6% of control, respectively) nor antiepan VEGFThe American Journal of Pathology - ajp.amjpathol.organtibody (93%  10%, 98%  16%, and 95%  12%) had
any effect at 1, 10, or 100 mg/mL, respectively. In contrast,
when combined with oxaliplatin anti-VEGF165b treatment
resulted in a signiﬁcant increase in the proportion of dead
cells after 24 hours compared with mouse IgG (Figure 5C).
As a more sensitive measure we also used the PrestoBlue
cell viability assay where absorption is proportional to923
Figure 4 VEGF-A165b protects retinal neurons from ischemia induced cell death in vivo. A: Pseudo-colored ﬂuorescent images of retinal cells revealing the
contralateral nonischemic retina, ischemic eye injected with HBSS, or ischemic eye injected with VEGF-A165b. B: Staining of retinae of HBSS- or VEGF-
A165beinjected rats for activated caspase 3 (red) and nuclei (blue). C: Live RGC counts were signiﬁcantly lower in ischemic eyes compared with nonischemic
eyes. VEGF-A165b treatment resulted in more viable RGCs (n Z 8 HBSS, n Z 12 VEGF-A165b, P < 0.001, analysis of variance plus Bonferroni post hoc test).
VEGF-A165b treatment increased the numbers of live Fluorogold-labeled retinal cells compared with the HBSS and control untreated eyes, which can be clearly
seen in D. The ratio of RGCs per ﬁeld in the ischemic and nonischemic eyes were compared. E: Neuroprotection by VEGF-A165b was mediated through
an inhibition of apoptosis, as indicated by a reduction in active caspase-3 staining, in both the RGCs and inner nuclear layer (INL). Data are means  SEM.
**P < 0.01, ***P < 0.001 compared with contralateral and yyyP < 0.001 compared with HBSS.
Beazley-Long et almitochondrial metabolic activity and can be taken as
a measure of cell viability, in which oxaliplatin also resulted
in signiﬁcant reduction in cell viability, which was further
reduced by the addition of anti-VEGF165b (Figure 5D).
Staining of cultured DRG neurons for VEGFR2 revealed
strong expression on the cell membrane (Figure 6A). To
investigate the receptor mediating the neuroprotective
response to VEGF-A165b, DRG cultures were treated with
10 nmol/L speciﬁc VEGFR2 inhibitor ZM323881 or
vehicle during oxaliplatin treatment and stained for NeuN
and activated caspase-3 (Figure 6B). Treatment with 20
mg/mL of oxaliplatin, either alone or with ZM323881,
induced a signiﬁcant increase in the percentage of acti-
vated caspase-3epositive, NeuN-positive cells compared924with media (51.4%  3.0% and 55.7%  1.9% versus
37.8%  1.3% and 42.5%  2.6%, respectively).
Concurrent treatment with 2.5 nmol/L recombinant human
VEGF-A165b without ZM323881 signiﬁcantly reduced the
percentage of activated caspase-3epositive, NeuN-positive
cells compared with vehicle (35.4%  3.1%) (Figure 6B),
and this effect was blocked by treatment with the VEGFR2
inhibitor ZM323881 (54.3%  3.3%). To further rule out
a role for VEGFR1, cells were treated with placenta
growth factor (PlGF), which activates only VEGFR1. This
neither affected the oxaliplatin-induced cell death nor
prevented its amelioration by VEGF165b (Figure 6B). As
an additional control to determine whether VEGF165b
was acting through VEGFR2, cells were treated withajp.amjpathol.org - The American Journal of Pathology
Figure 5 VEGF-A165b is cytoprotective for
primary sensory neurons. A: Effect of VEGF-A165b in
a model of chemotherapeutic-induced neurotoxicity.
Primary adult rat DRG cultures were treated with
increasing concentrations (0, 5, 10, and 20 mg/mL)
of the chemotherapeutic oxaliplatin for 24 hours
with or without 2.5 nmol/L VEGF-A165b (after 16
hours of pretreatment). The percentage of activated
caspase-3epositive NeuN-positive cells was deter-
mined after immunoﬂuorescence analysis. The
percentage of neurons positive for activated
caspase-3 was determined after treatment with 0 to
20 mg/mL of oxaliplatin for 24 hours with or without
2.5 nmol/L VEGF-A165b. VEGF-A165b treatment
inhibited oxaliplatin-induced caspase-3 expression.
Data are means  SEM (n Z 3). B: Representative
images of NeuN-positive cells after treatment. NeuN-
negative cells (only blue or blue and red) were not
counted. Arrows signify activated caspase-3 detec-
ted both around and in neuronal nuclei. C: Primary
DRG neurons were pretreated with concentrations of
a neutralizing VEGF165b antibody for 20 hours before
oxaliplatin treatment (0, 10 mg/mL; 24 hours). IgG
content was equalized for the groups by addition of
control mouse IgG. Pretreatment with anti-VEGF165b
did not affect the proportion of live neurons without
oxaliplatin treatment. The percentage of live neu-
rons was signiﬁcantly decreased by anti-VEGF165b
after oxaliplatin treatment. D: Cell viability was
measured by PrestoBlue absorbance from DRG neu-
rons treated as above. Oxaliplatin treatment signif-
icantly decreased the viability without anti-VEGF165b
pretreatment compared with control. VEGF165b
pretreatment reduced the viability further still
compared with control, which was signiﬁcant from
oxaliplatin treatment without anti-VEGF165b. Data
are means  SEM, nZ 6, one-way analysis of vari-
ance plus Bonferroni. *P< 0.05, **P< 0.01, ***P<
0.001, comparedwith nooxaliplatin plus IgG control;
yP < 0.05 compared with oxaliplatin IgG control.
Neuroprotective VEGF165boxaliplatin and VEGF165b in the presence of either mouse
IgG as a control or the VEGFR2 neutralizing antibody
DC101. Although VEGFR2 blockade by itself did not
increase neuronal caspase activity or affect the oxaliplatin-
induced effect, it prevented the VEGF165b-mediated
cytoprotection (Figure 6C).
To determine whether systemic administration of VEGF-
A165b could be neuroprotective, we used a mouse model of
peripheral traumatic nerve injury that results in activation of
injury-response genes in DRG neurons, such as galanin,30
and ATF3 (Figure 7, A and B). Biweekly treatment with
rhVEGF-A165b reduced the intensity of neuronal ATF3
expression in L3/4 DRG compared with sham surgery
controls after 10 days (Figure 7C).Discussion
We report that, like VEGF-A165a, the splice isoform VEGF-
A165b is neuroprotective for central and peripheral neurons,The American Journal of Pathology - ajp.amjpathol.orgin vitro and in vivo, and mediates this neuroprotective effect
through VEGFR2 and MEK1/2 activation. In addition to its
neuroprotective effects, VEGF-A165b also has neurotrophic
actions on neurons.
VEGF-A165a has been found to play a key role in
neuronal protection, in addition to its actions on the
vasculature, directly protecting motoneurons under condi-
tions of hypoxia, oxidative stress, and serum deprivation.31
Disturbance of VEGF-A expression contributes to the
development of amyotrophic lateral sclerosis in humans.29
VEGF-A and its receptors are also expressed in central
and peripheral nervous system support cells, such as astro-
cytes and Schwann cells, thereby also contributing to
neuronal survival and growth.10,32
In the central nervous system, VEGF-A165a protects
hippocampal, cortical, and cerebellar granule neurons against
numerous insults33e36 through VEGFR2, signaling through
activation of multiple intracellular pathways, including phos-
pholipase C, PI3K, and MEK1/2,32 whereas effects on sup-
porting cells, such as Schwann cells, and astrocytes, are925
Figure 6 Neuroprotection is mediated through VEGFR2 not VEGFR1. A: Primary cultured DRG were stained for bIII tubulin (green), VEGFR2 (red), and
Hoechst (blue). bIII tubulinepositive cells were also positive for VEGFR2, with the receptor detected in the soma (white arrows) and along cellular projections
(arrowheads). Some VEGFR2 detection did not colocalize to bIII tubulin (cyan arrows). The matched-species IgG-negative control conﬁrms the detection of
VEGFR2 expression. B: Treatment of DRG cultures with oxaliplatin plus 2.5 nmol/L VEGF-A165b and 10 nmol/L VEGFR2 inhibitor ZM323881 blocked the neu-
roprotection exerted by VEGF-A165b in the presence of ZM vehicle. Treatment of DRG cultures with 10 nmol/L PlGF, a competitor for VEGFR1, did not affect
rhVEGF165b neuroprotection against oxaliplatin. C: Treatment of DRG cultures with oxaliplatin plus 2.5 nmol/L VEGF-A165b and 10 mg/mL of VEGFR2 blocking
antibody DC101 blocked the neuroprotection exerted by VEGF-A165b in the presence of rat IgG. Data are means  SEM, (nZ 3), one-way analysis of variance
plus Newman Keuls. **P < 0.01, ***P < 0.001, compared with no oxaliplatin; yP < 0.05, compared with respective concentration matched vehicle; and ns are
compared with respective oxaliplatin without VEGF165b;
zzP < 0.01, zzzP < 0.001, compared with respective oxaliplatin without VEGF165b;
xP < 0.05, compared
with oxaliplatin and VEGF165b. Scale bar Z 50 mm.
Beazley-Long et algenerally mediated through VEGFR1.10 In contrast, our data
indicate that neuroprotection by VEGF-A165b in hippocampal
neurons, although also mediated through VEGFR2, involves
MEK1/2 but not either PI3K or p38 MAPK. The VEGF-Axxx
bisoforms compete for and inhibit VEGF-Axxxa binding at926VEGFR2,5,7,37 but the VEGF-Axxxb isoforms are not simply
competitive inhibitors of the VEGFR2 because binding of
VEGF-A165b results in differential tyrosine residue phos-
phorylation of VEGFR2.24 Neuroprotective and neurotrophic
actions by VEGF-A165a may also involve the VEGFajp.amjpathol.org - The American Journal of Pathology
Figure 7 VEGF-A165b is neuroprotective for DRG neurons in vivo. PSNI
was performed on anesthetized C57BL/6 mice, test compounds were
administered biweekly by i.p. injection after surgery, and L4 DRG was
harvested 14 days later. For each DRG a complete cross section proﬁle
was analyzed for ATF3 immunoﬂuorescence intensity. A: Low-power
representative images of ATF3 immunoﬂuorescence intensities from
whole ipsilateral L4 DRG sections and a species- and concentration-
matched IgG negative control. B: Mean pixel intensity was calculated
for each DRG proﬁle and expressed relative to the mean pixel intensity
for L4 DRG in the sham surgery group. PSNI increased ATF3 staining,
which was blocked by VEGF-A165b treatment. Results are means  SEM,
n Z 3 per group. Statistical analysis was performed with Kruskal-Wallis
and Dunn’s multiple comparison test: test group ipsilateral DRG intensity
versus ipsilateral DRG in the sham surgery group. *P < 0.05. C: DRG
ipsilateral to the injury was stained for ATF3 and the neuronal marker
NeuN to identify nerve injuryeinduced neuronal ATF3 expression. Scale
bar Z 500 mm.
Neuroprotective VEGF165b
The American Journal of Pathology - ajp.amjpathol.orgco-receptor neuropilin-1 (NP-1)32; VEGF-A165b binds weakly
to NP-1 and does not require NP-1 binding to phosphorylate
and activate VEGFR2.24 Our data support the conclusion that
the differential VEGFR2 phosphorylation and MEK1/2 acti-
vation exerted by VEGF-A165b is sufﬁcient to protect central
and peripheral neurons, without NP-1 binding. Our data on
both central nervous system and peripheral sensory neurons
indicate that the neuroprotective mechanism of VEGF-A165b
is like that ascribed to VEGF-A165a in that neuroprotection
occurs through prevention of caspase-3 induction.32
In the eye, endogenous VEGF-A is a survival factor for
RGCs, protecting against ischemia-reperfusion injury38 and
preventing neuronal apoptosis without the necessity for
NP-1 binding because VEGF-A120a (which lacks the NP-1
binding domain39) also exerted neuroprotective effects.
Our ﬁndings indicate that exogenous VEGF-A165b can
reduce both RGC and inner nuclear cell loss through
VEGFR2 activation. The loss of neuronal retrograde trans-
port is seen clinically in diabetic retinopathy as cotton wool
spots under fundus examination, and the loss of ganglion
cells contributes to vision loss in glaucoma.40 We have
previously found that VEGF-A165b is cytoprotective for
endothelial and retinal pigmented epithelial cells,41 whereas
it is antiangiogenic in the eye.42 Prevention of the ischemia-
induced damage to neurons in the retina by VEGF-A165b
would therefore also be a substantial advantage in thera-
peutic approaches for diabetic retinopathy and glaucoma.
In hippocampal and peripheral sensory cultured neurons,
VEGF-A165b also enhances neurite outgrowth, demon-
strating that VEGF-A165b exerts neurotrophic effects, also
through VEGFR2. In peripheral sensory and autonomic
neurons, VEGF-A165a enhances neuronal neurite outgrowth
in culture.11,32,43 VEGFR2 is expressed in both the central
and peripheral nervous systems but often in different
neuronal populations from VEGF-A proteins.44,45 These
different distributions suggest that VEGF-A isoforms exert
paracrine actions on neurons through which neuroprotective
and neurotrophic effects may be mediated. We demonstrate
that VEGF-A165b is a major VEGF-A splice variant
commonly found in central and peripheral neurons, where it
is well placed to exert such paracrine effects. VEGF-A165b
is also expressed in human skin, prostate, and kidney,
among other tissues,5,46 where it could also exert paracrine
effects on peripheral sensory neurons.
VEGF-A165b has clear inhibitory effects on tumor
growth5,14,47 but does not result in hypotension, angiogenesis,
or proteinuria.5,6,48 Our data indicate that VEGF-A165b has
neuroprotective effects similar to those ascribed to VEGF-
A165a, on central and peripheral neurons. VEGF-Aedependent
neovascularization is key in the pathophysiology of many
conditions, and antieVEGF-A therapies have entered clinical
practice in oncology9 and ophthalmology.8 After preclinical
studies of VEGF-A administration in neurodegenerative dis-
ease,11,29,49e51VEGF-A supplementation is now under trial for
treatment of neuronal degenerative diseases, for instance in
diabetic neuropathy.52 Although effective in some patients,927
Beazley-Long et althere has to be some concern about the safety proﬁle of these
strategies in relation to the potential compromise of non-
endothelial tissue and cell function in which VEGF-A has been
found to have protective properties, particularly neurons10 and
podocytes.53 We report that VEGF-Axxxb can exert similar
neuroprotective and neurotropic effects with VEGF-Axxxa both
centrally (eg, hippocampal neurons in culture, and retinal
neurons in vivo) and peripherally.
With the requirement that therapy for pathological
conditions in which VEGF-A has been implicated should
not adversely affect the function of the normal vasculature
or other cell types, we suggest that VEGF-A165b may be an
alternative therapeutic agent in neurodegenerative condi-
tions with fewer adverse vascular effects.References
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